Other OTC - Delayed Quote USD

International Stem Cell Corporation (ISCO)

0.0612

-0.0038

(-5.85%)

At close: April 26 at 2:59 PM EDT

Currency in USD All numbers in thousands

Download

Breakdown

TTM

12/31/2023

12/31/2022

12/31/2021

12/31/2020

Total Revenue

7,789.0000

8,180.0000

7,176.0000

7,128.0000

Cost of Revenue

3,181.0000

3,269.0000

2,935.0000

2,781.0000

Gross Profit

4,608.0000

4,911.0000

4,241.0000

4,347.0000

Operating Expense

5,271.0000

5,094.0000

6,162.0000

7,165.0000

Operating Income

-663.0000

-183.0000

-1,921.0000

-2,818.0000

Net Non Operating Interest Income Expense

-139.0000

-135.0000

-128.0000

-113.0000

Other Income Expense

671.0000

-13.0000

1,150.0000

207.0000

Pretax Income

-131.0000

-331.0000

-899.0000

-2,724.0000

Net Income Common Stockholders

-131.0000

-331.0000

-899.0000

-2,724.0000

Diluted NI Available to Com Stockholders

-131.0000

-331.0000

-899.0000

-2,724.0000

Basic EPS

-0.02

-0.04

-0.11

-0.36

Diluted EPS

-0.02

-0.04

-0.11

-0.36

Basic Average Shares

8,004.3890

7,833.0000

7,539.0000

Diluted Average Shares

8,004.3890

7,833.0000

7,539.0000

Total Operating Income as Reported

-663.0000

-183.0000

-1,921.0000

-2,818.0000

Total Expenses

8,452.0000

8,363.0000

9,097.0000

9,946.0000

Net Income from Continuing & Discontinued Operation

-131.0000

-331.0000

-899.0000

-2,724.0000

Normalized Income

-794.0000

-331.0000

-2,036.0000

-2,931.0000

Interest Expense

139.0000

135.0000

128.0000

113.0000

Net Interest Income

-139.0000

-135.0000

-128.0000

-113.0000

EBIT

8.0000

-196.0000

-771.0000

-2,611.0000

EBITDA

202.0000

22.0000

-509.0000

-2,358.0000

Reconciled Cost of Revenue

3,181.0000

3,269.0000

2,935.0000

2,781.0000

Reconciled Depreciation

194.0000

218.0000

262.0000

253.0000

Net Income from Continuing Operation Net Minority Interest

-131.0000

-331.0000

-899.0000

-2,724.0000

Total Unusual Items Excluding Goodwill

663.0000

1,137.0000

207.0000

Total Unusual Items

663.0000

1,137.0000

207.0000

Normalized EBITDA

-461.0000

22.0000

-1,646.0000

-2,565.0000

12/31/2020 - 5/1/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

HMTXF Hemostemix Inc.

0.0371

0.00%

LCTX.TA Lineage Cell Therapeutics, Inc.

418.00

-5.11%

REPCF RepliCel Life Sciences Inc.

0.0428

0.00%

SER Serina Therapeutics, Inc.

9.19

0.00%

USRM U.S. Stem Cell, Inc.

0.0001

0.00%

CLDX Celldex Therapeutics, Inc.

36.30

+0.11%

TRVN Trevena, Inc.

0.3910

-4.40%

LCTX Lineage Cell Therapeutics, Inc.

1.1400

+2.70%

BSEM BioStem Technologies, Inc.

9.11

-3.14%

FATE Fate Therapeutics, Inc.

3.8000

-1.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

International Stem Cell Corporation (ISCO)

Upgrade to begin using 40 years of financial statements and get so much more.

Related Tickers